Medexus Pharma
As of the edition of 20 October 2026, Medexus Pharma runs 4 drugs, 3 of them marketed.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 3 |
| Status not established | 1 |
| Total | 4 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Methotrexate | none listed | 2 |
| Treosulfan | Ends 2032 (exclusivity) | 0 |
| Rupatadine | none listed | 1 |
A route B row is one company at one target.
Where its trials are
- Blood and lymph: 1 trials led
- Inherited and neonatal: 1 trials led